Psychedelic Neuroscience: Volume 242
Published on 26. November 2018
Book
Hardback
261 pages
978-0-12-814255-4 (ISBN)
Description
We are in the midst of what is being called the 'psychedelic renaissance' with growing interest into how psychedelics alter consciousness, brain function and brain connectivity. The acute, often profound, effects of the psychedelic experience can induce lasting improvements in mental health demonstrating that chemistry forms the basis of mystical experience, consciousness and mental wellbeing.
More details
Series
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
This volume will interest policy makers, mental health practitioners, neuroscience researchers, researchers from various fields of health science and the humanities, members of the public and psychonauts.
Dimensions
Height: 235 mm
Width: 191 mm
Weight
720 gr
ISBN-13
978-0-12-814255-4 (9780128142554)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Person
Dr. Tanya Calvey has a background in evolutionary neurobiology and lectures morphological anatomy in the Faculty of Health Sciences, University of the Witwatersrand. Tanya's current research is on the neuropsychopharmacology of ibogaine and substance use disorders in humans and animals. Her research team is multidisciplinary and her research is funded by the South African Medical Research Council, the South African National Research Foundation and the International Society for Neurochemistry.
Tanya is also actively involved in developing neuroscience research in Africa. She is the Secretary of the Southern African Neuroscience Society and the co-founder of the Wits Cortex Club.
Tanya is also actively involved in developing neuroscience research in Africa. She is the Secretary of the Southern African Neuroscience Society and the co-founder of the Wits Cortex Club.
Content
1. An introduction to psychedelic neuroscience
Tanya Calvey and Fleur M. Howells
2. The renaissance in psychedelic research: What do preclinical models have to offer
Kevin S. Murnane
3. D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders
Danilo De Gregorio, Justine P. Enns, Nicolas A. Nunez, Luca Posa and Gabriella Gobbi
4. Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition
Selen Atasoy, Jakub Vohryzek, Gustavo Deco, Robin L. Carhart-Harris and Morten L. Kringelbach
5. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Joseph Barsuglia, Martin Polanco, Robert Palmer, Benjamin Malcolm, Benjamin Kelmendi and Tanya Calvey
6. Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain
Felix Mueller, Matthias E. Liechti, Undine E. Lang and Stefan Borgwardt
7. Neurocognitive effects of cannabis: Lessons learned from human experimental studies
Marco Colizzi and Sagnik Bhattacharyya
8. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers
John Martin Corkery
Tanya Calvey and Fleur M. Howells
2. The renaissance in psychedelic research: What do preclinical models have to offer
Kevin S. Murnane
3. D-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders
Danilo De Gregorio, Justine P. Enns, Nicolas A. Nunez, Luca Posa and Gabriella Gobbi
4. Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition
Selen Atasoy, Jakub Vohryzek, Gustavo Deco, Robin L. Carhart-Harris and Morten L. Kringelbach
5. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Joseph Barsuglia, Martin Polanco, Robert Palmer, Benjamin Malcolm, Benjamin Kelmendi and Tanya Calvey
6. Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain
Felix Mueller, Matthias E. Liechti, Undine E. Lang and Stefan Borgwardt
7. Neurocognitive effects of cannabis: Lessons learned from human experimental studies
Marco Colizzi and Sagnik Bhattacharyya
8. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers
John Martin Corkery